CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
E M
EM
Peñas-Lledó
H D
HD
Trejo
P
P
Dorado
A
A
Ortega
H
H
Jung
E
E
Alonso
M E G
ME
Naranjo
M
M
López-López
A
A
Llerena
D000639:Amitriptyline / Q000009:adverse effects* / Q000097:blood; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000097:blood; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects* / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008800:Mexico; D011110:Polymorphism, Genetic; D013997:Time Factors
D000928:Antidepressive Agents; D005473:Fluoxetine; D000639:Amitriptyline; D019389:Cytochrome P-450 CYP2D6